Literature DB >> 15671854

Inflammation-induced GDNF improves locomotor function after spinal cord injury.

Manabu Hashimoto1, Atsumi Nitta, Hidefumi Fukumitsu, Hiroshi Nomoto, Liya Shen, Shoei Furukawa.   

Abstract

Activation of microglia/macrophages after injury occurs limitedly in the CNS, which finding may explain unsuccessful axonal regeneration. Therefore, the relationship between lipopolysaccharide (LPS)-induced inflammation and recovery of locomotor function of rats after spinal cord injury was examined. High-dose LPS improved locomotor function greater than low-dose LPS, being consistent with the expression of neurotrophic factor (GDNF) in microglia/macrophages. Experiments using GDNF gene mutant mice confirmed that the increase in the GDNF mRNA level, rather than the reduction in the mRNA level of inducible NO synthase, could be correlated with the restoration activity of locomotor function. These results suggest that a higher degree of inflammation leads to a higher degree of repair of CNS injuries through GDNF produced by activated microglia/macrophages.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671854     DOI: 10.1097/00001756-200502080-00004

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  26 in total

Review 1.  Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury.

Authors:  Dustin J Donnelly; Phillip G Popovich
Journal:  Exp Neurol       Date:  2007-06-30       Impact factor: 5.330

2.  Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.

Authors:  Bin Xing; Tao Xin; Lingling Zhao; Randy L Hunter; Yan Chen; Guoying Bing
Journal:  J Neuroimmunol       Date:  2010-05-14       Impact factor: 3.478

3.  Differential expression of class 3 and 4 semaphorins and netrin in the lamprey spinal cord during regeneration.

Authors:  Michael I Shifman; Michael E Selzer
Journal:  J Comp Neurol       Date:  2007-04-01       Impact factor: 3.215

4.  Cell cycle activation and CNS injury.

Authors:  Bogdan A Stoica; Kimberly R Byrnes; Alan I Faden
Journal:  Neurotox Res       Date:  2009-04-21       Impact factor: 3.911

5.  Intravenous immune-modifying nanoparticles as a therapy for spinal cord injury in mice.

Authors:  Su Ji Jeong; John G Cooper; Igal Ifergan; Tammy L McGuire; Dan Xu; Zoe Hunter; Sripadh Sharma; Derrick McCarthy; Stephen D Miller; John A Kessler
Journal:  Neurobiol Dis       Date:  2017-08-18       Impact factor: 5.996

Review 6.  Chemical priming for spinal cord injury: a review of the literature part II-potential therapeutics.

Authors:  Martin M Mortazavi; Ketan Verma; Aman Deep; Fatemeh B Esfahani; Patrick R Pritchard; R Shane Tubbs; Nicholas Theodore
Journal:  Childs Nerv Syst       Date:  2010-12-21       Impact factor: 1.475

Review 7.  Dealing with Danger in the CNS: The Response of the Immune System to Injury.

Authors:  Sachin P Gadani; James T Walsh; John R Lukens; Jonathan Kipnis
Journal:  Neuron       Date:  2015-07-01       Impact factor: 17.173

8.  Systemic LPS induces spinal inflammatory gene expression and impairs phrenic long-term facilitation following acute intermittent hypoxia.

Authors:  A G Huxtable; S M C Smith; S Vinit; J J Watters; G S Mitchell
Journal:  J Appl Physiol (1985)       Date:  2013-01-17

9.  Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice.

Authors:  Ravid Shechter; Anat London; Chen Varol; Catarina Raposo; Melania Cusimano; Gili Yovel; Asya Rolls; Matthias Mack; Stefano Pluchino; Gianvito Martino; Steffen Jung; Michal Schwartz
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

10.  Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma.

Authors:  Genell D Hilton; Bogdan A Stoica; Kimberly R Byrnes; Alan I Faden
Journal:  J Cereb Blood Flow Metab       Date:  2008-07-09       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.